{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-24-000105","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.818090+00:00","generated_at":"2026-05-31T10:20:44.259173+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kiora reports Q2 net loss $2.2M, cash $27.8M; advancing two Phase 2 retinal trials","bullets":["Q2 revenue $20K (grant); net R&D expense $0.9M after $1.1M TOI reimbursement credits.","Cash, equivalents and short-term investments $27.8M; plus receivables/Tax credits $3.7M; runway into 2027.","Phase 2 ABACUS-2 trial of KIO-301 for retinitis pigmentosa design finalized; initiation expected 2H 2024.","Phase 2 CLARITY trial of KIO-104 for retinal inflammation planned to start 1H 2025, building on Phase 1b.","Melissa Tosca promoted to CFO; Lisa Walters-Hoffert appointed to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-24-000105","json":"https://secwatch.observer/filing/0001372514-24-000105.json","markdown":"https://secwatch.observer/filing/0001372514-24-000105.md","text":"https://secwatch.observer/filing/0001372514-24-000105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251424000105/0001372514-24-000105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251424000105/kprx-20240809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:20:44.259173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}